Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
11018166 | Urologic Oncology: Seminars and Original Investigations | 2018 | 8 Pages |
Abstract
This phase II study demonstrates that intravesical CG0070 yielded an overall 47% CR rate at 6 months for all patients and 50% for patients with CIS, with an acceptable level of toxicity for patients with high-risk BCG-unresponsive NMIBC. There is a particularly strong response and limited progression in patients with pure CIS.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Vignesh T. M.D., Donald L. M.D., Daniel A. M.D., Andrew M.D., Benjamin M.D., Ronald L. M.D., William M.D., Michael M.D., Igor M.D., Karim M.D., A. Karim M.D., Dominic M.S., John M.D., Arthur M.S., Alex W. M.S., Gary D. M.D.,